Radical Treatment Without Cure: Decision-making in Oligometastatic Prostate Cancer

Martin J.  Connor; Vincent Khoo; Verity Watson; Ahmed Hashim

doi:10.1016/j.eururo.2021.01.029

Radical Treatment Without Cure: Decision-making in Oligometastatic Prostate Cancer

Martin J. Connor^* (Corresponding Author), Vincent Khoo, Verity Watson, Ahmed Hashim

^*Corresponding author for this work

Health Economics Research Unit

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

An estimated 9596 men will be diagnosed with metastatic hormone-sensitive prostate cancer (mHSPC) at presentation in the USA in 2020 [1]. The incidence is predicted to increase to 15 097 diagnoses per year by 2025 [2]. Promisingly, the use of upfront systemic agents such as docetaxel, enzalutamide, abiraterone acetate, and apalutamide, in addition to androgen deprivation therapy (ADT), at diagnosis has led to an impressive increase in overall survival (OS)
from 3.6 yr to a median of 4.8 yr

Original language	English
Pages (from-to)	558-560
Number of pages	3
Journal	European Urology
Volume	79
Issue number	4
Early online date	3 Feb 2021
DOIs	https://doi.org/10.1016/j.eururo.2021.01.029
Publication status	Published - Apr 2021

Bibliographical note

Acknowledgments: University College London Hospitals (UCLH) Charity
(Grant No. P83624/1348) & Wellcome Trust (Grant No. 204998/Z/16/Z).

Keywords

THERAPY

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.eururo.2021.01.029Licence: Unspecified

Cite this

@article{a3a4223074b648c592c78e23a7994cc8,

title = "Radical Treatment Without Cure: Decision-making in Oligometastatic Prostate Cancer",

abstract = "An estimated 9596 men will be diagnosed with metastatic hormone-sensitive prostate cancer (mHSPC) at presentation in the USA in 2020 [1]. The incidence is predicted to increase to 15 097 diagnoses per year by 2025 [2]. Promisingly, the use of upfront systemic agents such as docetaxel, enzalutamide, abiraterone acetate, and apalutamide, in addition to androgen deprivation therapy (ADT), at diagnosis has led to an impressive increase in overall survival (OS)from 3.6 yr to a median of 4.8 yr",

keywords = "THERAPY",

author = "Connor, {Martin J.} and Vincent Khoo and Verity Watson and Ahmed Hashim",

note = "Acknowledgments: University College London Hospitals (UCLH) Charity (Grant No. P83624/1348) & Wellcome Trust (Grant No. 204998/Z/16/Z).",

year = "2021",

month = apr,

doi = "10.1016/j.eururo.2021.01.029",

language = "English",

volume = "79",

pages = "558--560",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier",

number = "4",

}

TY - JOUR

T1 - Radical Treatment Without Cure

T2 - Decision-making in Oligometastatic Prostate Cancer

AU - Connor, Martin J.

AU - Khoo, Vincent

AU - Watson, Verity

AU - Hashim, Ahmed

N1 - Acknowledgments: University College London Hospitals (UCLH) Charity (Grant No. P83624/1348) & Wellcome Trust (Grant No. 204998/Z/16/Z).

PY - 2021/4

Y1 - 2021/4

N2 - An estimated 9596 men will be diagnosed with metastatic hormone-sensitive prostate cancer (mHSPC) at presentation in the USA in 2020 [1]. The incidence is predicted to increase to 15 097 diagnoses per year by 2025 [2]. Promisingly, the use of upfront systemic agents such as docetaxel, enzalutamide, abiraterone acetate, and apalutamide, in addition to androgen deprivation therapy (ADT), at diagnosis has led to an impressive increase in overall survival (OS)from 3.6 yr to a median of 4.8 yr

AB - An estimated 9596 men will be diagnosed with metastatic hormone-sensitive prostate cancer (mHSPC) at presentation in the USA in 2020 [1]. The incidence is predicted to increase to 15 097 diagnoses per year by 2025 [2]. Promisingly, the use of upfront systemic agents such as docetaxel, enzalutamide, abiraterone acetate, and apalutamide, in addition to androgen deprivation therapy (ADT), at diagnosis has led to an impressive increase in overall survival (OS)from 3.6 yr to a median of 4.8 yr

KW - THERAPY

UR - http://www.scopus.com/inward/record.url?scp=85101287503&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2021.01.029

DO - 10.1016/j.eururo.2021.01.029

M3 - Article

C2 - 33549359

SN - 0302-2838

VL - 79

SP - 558

EP - 560

JO - European Urology

JF - European Urology

IS - 4

ER -

Radical Treatment Without Cure: Decision-making in Oligometastatic Prostate Cancer

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this